Loading organizations...
§ Private Profile · 1590 BUNKER CRT CHAMBERSBURG, PA 17202 United States
SIRPant Immunotherapeutics is a company.
Key people at SIRPant Immunotherapeutics.
SIRPant Immunotherapeutics develops next-generation, autologous macrophage-based cell therapies for oncology, with its lead product, SIRPant-M, targeting solid tumors. The company's technical approach centers on utilizing SIRPαlow-activated macrophages to activate phagocytes, circumventing the suppressive tumor microenvironment to eliminate cancer cells and foster lasting anti-cancer immunity. This innovative adoptive cell therapy involves a patient's own cells, which are then enhanced and returned to the body, offering a unique mechanism distinct from traditional viral or genetic reprogramming methods.
The company was co-founded by Robert Towarnicki and Nathanael Mccurley around 2020, stemming from an insight into the potential of reprogrammed macrophages to overcome cancer's defenses. This foundational idea aimed to leverage the body's intrinsic immune capabilities more effectively against aggressive malignancies, building upon the founders' understanding of cellular immunology and tumor biology.
SIRPant Immunotherapeutics primarily serves cancer patients, particularly those with solid tumors and initially focusing on indications such as T-cell lymphoma, for which SIRPant-M has received orphan drug designation. The company's vision is to offer novel and effective therapeutic options for individuals battling advanced and aggressive cancers, addressing the critical need for new treatments where conventional approaches often prove insufficient.
SIRPant Immunotherapeutics is a clinical-stage immuno-oncology company developing macrophage-based cell therapies for hematological malignancies and solid tumors, primarily targeting cancers like head & neck, colon, lung, pancreatic, cutaneous T-cell lymphoma, non-Hodgkin lymphoma, and others.[1][2][3][6] Its lead product, SIRPant-M™, is an autologous therapy that engineers a patient's own monocytes into SIRPαlow activated macrophages (M1 phenotype) to promote polyclonal anti-tumor immune responses, eliminating cancer cells body-wide by activating T-cells and antibodies without genetic engineering.[1][2][4] This addresses unmet needs in oncology by offering simpler, less toxic, and cheaper manufacturing compared to engineered cell therapies, serving healthcare providers and patients with aggressive, treatment-resistant tumors.[1][3][4] Founded in 2020 and headquartered in Hummelstown, Pennsylvania, the company raised a $27M Series A in 2021, filed an IND in Q1 2023 (cleared by FDA), and initiated Phase 1 trials in H2 2023 for solid tumors and recurrent non-Hodgkin lymphoma, with plans for Series B funding to expand clinical work.[2][3][6]
SIRPant Immunotherapeutics was founded in 2020 as a Delaware C-Corporation headquartered in Pennsylvania's Hershey Center for Applied Research, emerging from research into macrophage activation to bypass the immunosuppressive tumor microenvironment.[1][2][4] The core idea stems from preclinical work showing SIRPαlow macrophages rapidly eliminate metastatic solid tumors in mice (e.g., pancreatic, colorectal, melanoma, lung, breast), achieving 100% survival rates by inducing long-lasting anti-cancer immunity via a simple blood draw, cell processing, and reinfusion process.[4] Key leadership includes Robert Towarnicki, MS, President & CEO, who presented at BIO 2023, and recently appointed Jelle Kijlstra, MD, MBA, Chief Medical Officer, with 30+ years in drug development.[2][3] Pivotal early moments include the 2021 $27M Series A raise and FDA IND clearance for SIRPant-M in early 2023, enabling first-in-human Phase 1 studies shortly after.[2][3]
SIRPant rides the macrophage therapy wave in immuno-oncology, shifting from T-cell-centric approaches (e.g., CAR-T) to innate immune cells like macrophages, which better penetrate solid tumor microenvironments suppressed by "don't eat me" signals like CD47-SIRPα.[1][4] Timing aligns with surging demand for next-gen cell therapies post-2020s CAR-T limitations in solids, amid a biotech funding rebound and FDA nods for similar platforms.[3] Market tailwinds include a $50B+ oncology cell therapy space growing 20%+ annually, driven by failures of checkpoint inhibitors in cold tumors, positioning SIRPant to fill gaps in pancreatic, lung, and lymphoma treatments.[2][6] By pioneering non-genetic macrophage tech, it influences the ecosystem toward simpler, scalable therapies, potentially accelerating adoption via partnerships and lowering barriers for community hospitals.[1][2]
SIRPant is poised for Phase 1 readouts in 2024-2025 on SIRPant-M efficacy in hard-to-treat solids and lymphomas, with Series B funding likely fueling multi-indication trials and combo studies (e.g., with PD-1 inhibitors).[2][3][6] Trends like AI-optimized cell engineering and bispecifics will amplify macrophage platforms, but SIRPant's non-GMO edge could drive faster scaling and acquisitions by big pharma seeking solid tumor breakthroughs. Its influence may grow by validating macrophages as a frontline modality, reshaping immuno-oncology from T-cell dominance toward innate-adaptive synergies—potentially delivering the body-wide responses that current therapies promise but struggle to achieve.[1][4]
Key people at SIRPant Immunotherapeutics.
